Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B
The aim of this review is to outline emerging biomarkers that can serve as diagnostic tools to identify non-cirrhotic chronic hepatitis B (CHB) patients who could safely discontinue nucleos(t)ide analogues (NAs) before HBsAg loss. Regarding possible predictors of post-NAs outcomes, a number of studi...
Main Authors: | Margarita Papatheodoridi, George Papatheodoridis |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-02-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/9/2/493 |
Similar Items
-
Seroreversion and Acute Decompensation in Chronic Hepatitis B after Discontinuation of Oral Nucleotide Analog in the Patients Achieving HBsAg Loss
by: Hye Jeong Cho, et al.
Published: (2020-11-01) -
Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B
by: E K Ibragimov, et al.
Published: (2019-02-01) -
Distinct patterns of serum hepatitis B core-related antigen during the natural history of chronic hepatitis B
by: Zhan-Qing Zhang, et al.
Published: (2017-12-01) -
The Yin and the Yang of Treatment for Chronic Hepatitis B—When to Start, When to Stop Nucleos(t)ide Analogue Therapy
by: Samuel Hall, et al.
Published: (2020-08-01) -
Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients
by: Young Jip Kim, et al.
Published: (2013-09-01)